A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Adult patients, 18 to 65 years of age, inclusive

- Type 2 diabetes mellitus according to WHO criteria diagnosed for at least 3 months
prior to screening

- On stable dose of metformin for at least 2 months prior to screening

- Fasting plasma glucose during the screening period
- Hemoglobin A1c (HbA1c) levels at screening >/= 6.5% and
- Evidence of insulin secretory capacity at screening

- Body mass index (BMI) 27 to 42 kg/m2, inclusive

- Females of child-bearing potential and males with female partners of child-bearing
potential must agree to use effective contraception as defined by protocol

Exclusion Criteria:

- Type 1 diabetes

- Acquired or secondary forms of diabetes such as those resulting from pancreatic
surgery/injury, cystic fibrosis related diabetes

- History of acute metabolic complications such as diabetic ketoacidosis or state of
hyperosmolar hyperglycemia

- Evidence or history of clinically significant diabetic complications such as
clinically severe diabetic peripheral neuropathy, clinically significant nephropathy
as judged by the investigator, or pre-proliferative/proliferative diabetic
retinopathy as judged by the investigator

- History of severe symptomatic hypoglycemia (requiring assistances of a third party)
within 6 months prior to screening

- History or presence of clinically significant concomitant disease or disorder

- Hemoglobin level below the lower limit of reference range at screening

- Pregnant or lactating women

- History of anaphylaxis or severe systemic hypersensitivity or allergic reactions